Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used to treat type 2 diabetes mellitus (T2DM). They increase the bioavailability of endogenous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both GIP and GLP-1 might impact postprandial gallbladder motility, which raises concerns over the risk of gallbladder or biliary diseases following DPP-4 treatment. 1 Here's a Journal Watch that discusses a systemative review of the “ Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: a systematic review and pairwise and network meta-analysis of randomized controlled trials ” published in the BMJ , 2022 .
What was the need for the study? Previous studies suggested an association between gallbladder-related events and incretin-based drugs, including DPP-4 inhibitors and GLP-1 receptor agonists . 2…
